1
|
Tabor JK, Onoichenco A, Narayan V, Wernicke AG, D’Amico RS, Vojnic M. Brain metastasis screening in the molecular age. Neurooncol Adv 2023; 5:vdad080. [PMID: 37484759 PMCID: PMC10358433 DOI: 10.1093/noajnl/vdad080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/25/2023] Open
Abstract
The incidence of brain metastases (BM) amongst cancer patients has been increasing due to improvements in therapeutic options and an increase in overall survival. Molecular characterization of tumors has provided insights into the biology and oncogenic drivers of BM and molecular subtype-based screening. Though there are currently some screening and surveillance guidelines for BM, they remain limited. In this comprehensive review, we review and present epidemiological data on BM, their molecular characterization, and current screening guidelines. The molecular subtypes with the highest BM incidence are epithelial growth factor receptor-mutated non-small cell lung cancer (NSCLC), BRCA1, triple-negative (TN), and HER2+ breast cancers, and BRAF-mutated melanoma. Furthermore, BMs are more likely to present asymptomatically at diagnosis in oncogene-addicted NSCLC and BRAF-mutated melanoma. European screening standards recommend more frequent screening for oncogene-addicted NSCLC patients, and clinical trials are investigating screening for BM in hormone receptor+, HER2+, and TN breast cancers. However, more work is needed to determine optimal screening guidelines for other primary cancer molecular subtypes. With the advent of personalized medicine, molecular characterization of tumors has revolutionized the landscape of cancer treatment and prognostication. Incorporating molecular characterization into BM screening guidelines may allow physicians to better identify patients at high risk for BM development and improve patient outcomes.
Collapse
Affiliation(s)
| | | | - Vinayak Narayan
- Department of Neurological Surgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA
| | - A Gabriella Wernicke
- Department of Radiation Medicine, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA
| | - Randy S D’Amico
- Department of Neurological Surgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA
| | - Morana Vojnic
- Corresponding Author: Morana Vojnic, MD, MBA, 210 East 64th Street, Floor 4, New York, NY 10065, USA ()
| |
Collapse
|
2
|
Shim YB, Byun JY, Lee JY, Lee EK, Park MH. Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data. PLoS One 2022; 17:e0274876. [PMID: 36126084 PMCID: PMC9488774 DOI: 10.1371/journal.pone.0274876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 09/06/2022] [Indexed: 11/19/2022] Open
Abstract
Brain metastases (BM) are common in patients with non-small cell lung cancer (NSCLC). However, the pure economic burden of BM is unknown. This study aimed to evaluate the impact of BM on healthcare costs and resource utilization in patients with NSCLC by comparing patients with and without BM. This was a retrospective cohort analysis of South Korean health insurance review and assessment claims data. Patients with stage IIIB or IV NSCLC were identified (March 1, 2013 to February 28, 2018). We compared their two-year and per-patient-per-month (PPPM) healthcare costs and resource utilization with 1:3 propensity score-matched patients without the condition. A generalized linear model was used to estimate the impact of BM and other covariates on healthcare costs. After propensity score matching with the 33 402 newly diagnosed cases of stage IIIB or IV NSCLC, 3435 and 10 305 patients were classified as having or not having BM, respectively. Mean healthcare costs were significantly greater in patients with BM for both the two years (US$ 44 692 vs. US$ 32 230, p < .0001) and PPPM (US$ 3510 vs. US$ 2573, p < .0001). The length of hospital stay was longer in patients with BM (79.15 vs. 69.41 days for two years, p < .0001; 7.69 vs. 6.86 days PPPM, p < .0001), and patients with BM had more outpatient visits (50.61 vs. 46.43 times for two years, p < .0001; 3.64 vs. 3.40 times PPPM costs, p < .0001). The costs of drugs, radiology/radiotherapy, and admission comprised the majority of PPPM costs and were higher in patients with BM. The generalized linear model analysis suggested that patients with BM had significantly increased healthcare costs (by 1.29-fold, 95% confidence interval 1.26–1.32). BM is a significant economic burden for patients with NSCLC. Therefore, it is important to prevent BM in patients with NSCLC to reduce their economic burden.
Collapse
Affiliation(s)
- Yoon-Bo Shim
- School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, South Korea
| | - Joo-Young Byun
- School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, South Korea
| | - Ju-Yong Lee
- School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, South Korea
- AstraZeneca Korea, Seoul, South Korea
| | - Eui-Kyung Lee
- School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, South Korea
| | - Mi-Hai Park
- School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, South Korea
- * E-mail:
| |
Collapse
|
3
|
Merkhofer CM, Eastman B, Densmore I, Halasz LM, McGranahan T, Baik C. Systemic Treatment Patterns and Outcomes in Patients with EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease. Clin Lung Cancer 2022; 23:446-455. [DOI: 10.1016/j.cllc.2022.03.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 02/14/2022] [Accepted: 03/27/2022] [Indexed: 11/28/2022]
|
4
|
Designing Patient-Driven, Tissue-Engineered Models of Primary and Metastatic Breast Cancer. Bioengineering (Basel) 2022; 9:bioengineering9020044. [PMID: 35200398 PMCID: PMC8869490 DOI: 10.3390/bioengineering9020044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 01/01/2022] [Accepted: 01/12/2022] [Indexed: 11/17/2022] Open
Abstract
The rising survival rate for early-stage breast cancer in the United States has created an expanding population of women in remission at risk for distant recurrence, with metastatic spread to the brain demonstrating an especially poor prognosis. The current standard of care for breast cancer brain metastases is not well defined or differentiated from the treatment of brain metastases from other primary sites. Here, we present tissue-engineered models of the primary and brain metastatic breast cancer microenvironments informed by analysis of patient tumor resections. We find that metastatic resections demonstrate distinct cellular and matrix components compared with primary resections or non-cancerous controls. Using our model systems, we find that the observed deposition of collagen I after metastasis to the brain may enhance breast cancer invasion. Future optimization of these models will present a novel platform to examine tumor-stroma interactions and screen therapeutics for the management of metastatic breast cancer.
Collapse
|
5
|
Schwartz NR, DeBusk K, Forero-Torres A, Feliciano J, Anupindi VR, Yeaw J, McBride A. Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer. Future Oncol 2021; 17:3457-3463. [PMID: 34044579 DOI: 10.2217/fon-2020-1292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: Compare healthcare resource utilization and costs among patients with HER2+ metastatic breast cancer (MBC) with and without central nervous system (CNS) metastases. Methods: Retrospective matched cohort study using IQVIA's PharMetrics® Plus claims database. Results: Patients with CNS metastases (n = 753) experienced more outpatient, emergency room and inpatient visits versus controls (n = 753; all p < 0.05). In the post-index year, median total all-cause healthcare costs were significantly higher among patients with CNS metastases versus controls ($112,402 vs $50,835; p < 0.0001); outpatient costs primarily drove the cost differential. Conclusion: More effective therapies are needed that improve clinical outcomes and reduce economic burden associated with CNS metastases in patients with HER2+ MBC.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Ali McBride
- University of Arizona Cancer Center, Phoenix, AZ 85004, USA.,The University of Arizona College of Pharmacy, Phoenix, AZ 85004, USA
| |
Collapse
|
6
|
Adil SM, Hodges SE, Edwards RM, Charalambous LT, Yang Z, Kiyani M, Musick A, Parente BA, Lee HJ, Peters KB, Fecci PE, Lad SP. Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States. Neurooncol Pract 2020; 7:636-645. [PMID: 33312678 DOI: 10.1093/nop/npaa041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background The economic burden of cancer in the United States is substantial, and better understanding it is essential in informing health care policy and innovation. Leptomeningeal carcinomatosis (LC) represents a late complication of primary cancer spreading to the leptomeninges. Methods The IBM MarketScan Research databases were queried for adults diagnosed with LC from 2001 to 2015, secondary to 4 primary cancers (breast, lung, gastrointestinal, and melanoma). Health care resource utilization (HCRU) and treatment utilization were quantified at baseline (1-year pre-LC diagnosis) and 30, 90, and 365 days post-LC diagnosis. Results We identified 4961 cases of LC (46.3% breast cancer, 34.8% lung cancer, 13.5% gastrointestinal cancer, and 5.4% melanoma). The median age was 57.0 years, with 69.7% female and 31.1% residing in the South. Insurance status included commercial (71.1%), Medicare (19.8%), and Medicaid (9.1%). Median follow-up was 66.0 days (25th percentile: 24.0, 75th percentile: 186.0) and total cumulative costs were highest for the gastrointestinal subgroup ($167 768) and lowest for the lung cancer subgroup ($145 244). There was considerable variation in the 89.6% of patients who used adjunctive treatments at 1 year, including chemotherapy (64.3%), radiotherapy (57.6%), therapeutic lumbar puncture (31.5%), and Ommaya reservoir (14.5%). The main cost drivers at 1 year were chemotherapy ($62 026), radiation therapy ($37 076), and specialty drugs ($29 330). The prevalence of neurologic impairments was 46.9%, including radiculopathy (15.0%), paresthesia (12.3%), seizure episode/convulsive disorder not otherwise specified (11.0%), and ataxia (8.0%). Conclusions LC is a devastating condition with an overall poor prognosis. We present the largest study of LC in this real-world study, including current treatments, with an emphasis on HCRU. There is considerable variation in the treatment of LC and significant health care costs.
Collapse
Affiliation(s)
- Syed M Adil
- Department of Neurosurgery, Duke University Medical Center, Durham, NC, US
| | - Sarah E Hodges
- Department of Neurosurgery, Duke University Medical Center, Durham, NC, US
| | - Ryan M Edwards
- Department of Neurosurgery, Duke University Medical Center, Durham, NC, US
| | | | - Zidanyue Yang
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, US
| | - Musa Kiyani
- Department of Neurosurgery, Duke University Medical Center, Durham, NC, US
| | - Alexis Musick
- Department of Neurosurgery, Duke University Medical Center, Durham, NC, US
| | - Beth A Parente
- Department of Neurosurgery, Duke University Medical Center, Durham, NC, US
| | - Hui-Jie Lee
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, US
| | - Katherine B Peters
- Department of Neurosurgery, Duke University Medical Center, Durham, NC, US.,The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, US
| | - Peter E Fecci
- Department of Neurosurgery, Duke University Medical Center, Durham, NC, US.,The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, US
| | - Shivanand P Lad
- Department of Neurosurgery, Duke University Medical Center, Durham, NC, US
| |
Collapse
|
7
|
Holbrook K, Lutzky J, Davies MA, Davis JM, Glitza IC, Amaria RN, Diab A, Patel SP, Amin A, Tawbi H. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer 2019; 126:523-530. [PMID: 31658370 PMCID: PMC7004095 DOI: 10.1002/cncr.32547] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 08/27/2019] [Accepted: 08/29/2019] [Indexed: 12/15/2022]
Abstract
Background Sixty percent of patients with stage IV melanoma may develop brain metastases, which result in significantly increased morbidity and a poor overall prognosis. Phase 3 studies of melanoma usually exclude patients with untreated brain metastases; therefore, clinical data for intracranial responses to treatments are limited. Methods A multicenter, retrospective case series investigation of consecutive BRAF‐mutant patients with melanoma brain metastases (MBMs) treated with a combination of BRAF inhibitor encorafenib and MEK inhibitor binimetinib was conducted to evaluate the antitumor response. Assessments included the intracranial, extracranial, and global objective response rates (according to the modified Response Evaluation Criteria in Solid Tumors, version 1.1); the clinical benefit rate; the time to response; the duration of response; and safety. Results A total of 24 patients with stage IV BRAF‐mutant MBMs treated with encorafenib plus binimetinib in 3 centers in the United States were included. Patients had received a median of 2.5 prior lines of treatment, and 88% had prior treatment with BRAF/MEK inhibitors. The intracranial objective response rate was 33%, and the clinical benefit rate was 63%. The median time to a response was 6 weeks, and the median duration of response was 22 weeks. Among the 21 patients with MBMs and prior BRAF/MEK inhibitor treatment, the intracranial objective response rate was 24%, and the clinical benefit rate was 57%. Similar outcomes were observed for extracranial and global responses. The safety profile for encorafenib plus binimetinib was similar to that observed in patients with melanoma without brain metastases. Conclusions Combination therapy with encorafenib plus binimetinib elicited intracranial activity in patients with BRAF‐mutant MBMs, including patients previously treated with BRAF/MEK inhibitors. Further prospective studies are warranted and ongoing. All clinical trials to date with encorafenib and binimetinib (US Food and Drug Administration–approved in June 2018 for BRAF‐mutated metastatic melanoma) have excluded untreated melanoma brain metastases. This case series provides the first clinical evidence of intracranial activity of the combination of encorafenib plus binimetinib in patients with BRAF‐mutant melanoma with active brain metastases. Intracranial clinical activity is observed for the first time in patients previously treated with BRAF/MEK inhibitors, a population that has not been previously investigated.
Collapse
Affiliation(s)
| | - Jose Lutzky
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida
| | - Michael A Davies
- The University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | | | - Rodabe N Amaria
- The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Adi Diab
- The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Sapna P Patel
- The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Asim Amin
- Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Hussein Tawbi
- The University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
8
|
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma Res 2019; 29:65-69. [PMID: 30376465 DOI: 10.1097/cmr.0000000000000527] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BRAF and MEK kinase inhibitors can be highly effective in treating BRAF-mutant melanomas, but their safety and activity in patients with active/symptomatic brain metastases are unclear. We sought to shed light on this open clinical question. We conducted a multicenter retrospective study on real-life patients with melanoma and active brain metastases treated with combination BRAF/MEK inhibitors. A total of 65 patients were included (38 men and 27 women; median age: 49 years). Of them, 53 patients received dabrafenib/trametinib, 10 received vemurafenib/cobimetinib, one received encorafenib/binimetinib, and one received vemurafenib/trametinib. We did not observe any unexpected treatment-related safety signals in our cohort. Overall, 17 patients continued on therapy through the cutoff date. After initiation of therapy, steroid dose could be decreased in 22 of 33 patients (11 tapered off entirely), anticonvulsants were stopped in four of 21, and narcotics were stopped in four of 12. Median progression-free survival from the start of therapy was 5.3 months (95% confidence interval: 3.6-6.1), and median overall survival was 9.5 months (95% confidence interval: 7.7-13.5). A total of 20 patients were surviving at the cutoff date. Univariate analysis of age, sex, ulceration status, thickness, stage, location, or lactate dehydrogenase did not reveal significant predictors of progression-free survival or overall survival within our cohort, but multivariate analysis suggested that older age, lower risk location of original lesion, and nodular melanoma are poor prognostic indicators. Combination therapy with BRAF/MEK inhibitors is a viable treatment option for patients with BRAF-mutant melanoma and brain metastases, but further studies should help to define the optimal treatment approach in this population.
Collapse
|
9
|
Kuroda H, Tachikawa M, Yagi Y, Umetsu M, Nurdin A, Miyauchi E, Watanabe M, Uchida Y, Terasaki T. Cluster of Differentiation 46 Is the Major Receptor in Human Blood-Brain Barrier Endothelial Cells for Uptake of Exosomes Derived from Brain-Metastatic Melanoma Cells (SK-Mel-28). Mol Pharm 2018; 16:292-304. [PMID: 30452273 DOI: 10.1021/acs.molpharmaceut.8b00985] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Brain metastasis is a frequent complication of cancer and may be mediated, at least in part, by the internalization of cancer-cell-derived exosomes into brain capillary endothelial cells. Clarifying the mechanism(s) of this internalization is of interest because it could help us to develop ways to block brain metastasis, as well as affording a potential new route for drug delivery into the brain. Therefore, the purpose of the present study was to address this issue by identifying the receptors involved in the internalization of exosomes derived from a brain-metastatic cancer cell line (SK-Mel-28) into human blood-brain barrier endothelial cells (hCMEC/D3 cells). The combination of sulfo-SBED-based cross-linking and comprehensive proteomics yielded 20 proteins as exosome receptor candidates in hCMEC/D3 cells. The uptake of PKH67-labeled exosomes by hCMEC/D3 cells measured at 37 °C was significantly reduced by 95.6% at 4 °C and by 15.3% in the presence of 1 mM RGD peptide, an integrin ligand. Therefore, we focused on the identified RGD receptors, integrin α5 and integrin αV, and CD46, which is reported to act as an adenovirus receptor, together with integrin αV. A mixture of neutralizing antibodies against integrin α5 and integrin αV significantly decreased the exosome uptake by 11.8%, while application of CD46 siRNA reduced it by 39.0%. Immunohistochemical analysis confirmed the presence of CD46 in human brain capillary endothelial cells. These results suggest that CD46 is a major receptor for the uptake of SK-Mel-28-derived exosomes by human blood-brain barrier endothelial cells (hCMEC/D3 cells).
Collapse
Affiliation(s)
- Hiroki Kuroda
- Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences , Tohoku University , Sendai 980-8578 , Japan
| | - Masanori Tachikawa
- Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences , Tohoku University , Sendai 980-8578 , Japan
| | - Yuta Yagi
- Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences , Tohoku University , Sendai 980-8578 , Japan
| | - Mina Umetsu
- Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences , Tohoku University , Sendai 980-8578 , Japan
| | - Armania Nurdin
- Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences , Tohoku University , Sendai 980-8578 , Japan
| | - Eisuke Miyauchi
- Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences , Tohoku University , Sendai 980-8578 , Japan
| | - Michitoshi Watanabe
- Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences , Tohoku University , Sendai 980-8578 , Japan
| | - Yasuo Uchida
- Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences , Tohoku University , Sendai 980-8578 , Japan
| | - Tetsuya Terasaki
- Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences , Tohoku University , Sendai 980-8578 , Japan
| |
Collapse
|
10
|
Aguiar PN, Haaland B, Park W, San Tan P, Del Giglio A, de Lima Lopes G. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2018; 4:1080-1084. [PMID: 29852038 PMCID: PMC6143050 DOI: 10.1001/jamaoncol.2018.1395] [Citation(s) in RCA: 93] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Accepted: 03/15/2018] [Indexed: 12/31/2022]
Abstract
Importance The survival of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the last decade with the development of targeted tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation TKI that is approved by the US Food and Drug Administration for the treatment of patients who develop EGFR T790M mutations, has recently shown improved clinical outcomes compared with gefitinib and erlotinib for treatment-naive patients. Objective The aim of this study was to assess the cost-effectiveness of osimertinib for the first-line treatment of patients with EGFR-mutated NSCLC. Design, Setting, and Participants For this cost-effectiveness analysis, we extracted individual patient data from the FLAURA randomized clinical trial and used findings of our earlier meta-analysis to develop a decision-analytic model and determine the cost-effectiveness of osimertinib (AZD9291) compared with first- and second-generation EGFR-TKIs over a 10-year time horizon. All direct costs were based on US and Brazilian payer perspectives. Main Outcomes and Measures The main outcome of this study was the incremental cost-effectiveness ratio (ICER) expressed as cost per quality-adjusted life-year (QALY) gained by using osimertinib compared with first- or second-generation EGFR-TKIs in previously untreated EGFR-mutated NSCLC. Results In the base case using the data as reported in the FLAURA trial, the incremental QALY for osimertinib was 0.594 compared with the first- and second-generation EGFR-TKIs. In the United States, the osimertinib ICERs were $226 527 vs erlotinib, $231 123 vs gefitinib, and $219 874 vs afatinib. In Brazil, the ICERs were $162 329, $180 804, and $175 432, respectively. The overall survival (95% CI) reported in the FLAURA trial (hazard ratio, 0.63; 95% CI, 0.45-0.88) had the strongest association with the ICER (ranging from $84 342 to $859 771). Osimertinib price adjustments to the FLAURA trial data improved cost-effectiveness. For example, a discount of 10% on osimertinib acquisition cost was associated with a 20% decreased ICER compared with the base case ICER, and a discount of 20% on osimertinib acquisition cost was associated with a 40% decreased ICER compared with the base case ICER. Conclusions and Relevance At current costs, by World Health Organization cost-effectiveness threshold criteria, osimertinib is not cost-effective for first-line therapy of EGFR-mutated NSCLC in either the United States or Brazil.
Collapse
Affiliation(s)
- Pedro N Aguiar
- Centro de Estudos e Pesquisa de Hematologia e Oncologia, Faculdade de Medicina do ABC, Santo André, Brazil
| | - Benjamin Haaland
- Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City
- Department of Internal Medicine, University of Utah, Salt Lake City
| | - Wungki Park
- Sylvester Comprehensive Cancer Center at the University of Miami, Miami, Florida
| | - Pui San Tan
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, England
| | - Auro Del Giglio
- Centro de Estudos e Pesquisa de Hematologia e Oncologia, Faculdade de Medicina do ABC, Santo André, Brazil
| | | |
Collapse
|
11
|
Heinzel A, Müller D, Yekta-Michael SS, Ceccon G, Langen KJ, Mottaghy FM, Wiesmann M, Kocher M, Hattingen E, Galldiks N. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. Neuro Oncol 2018; 19:1271-1278. [PMID: 28204572 DOI: 10.1093/neuonc/now310] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Background Conventional MRI is the standard method to diagnose recurrence of brain metastases after radiation. However, following radiation therapy, reactive transient blood-brain barrier alterations with consecutive contrast enhancement can mimic brain metastasis recurrence. Recent studies have suggested that O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET improves the correct differentiation of brain metastasis recurrence from radiation injury. Based on published evidence and clinical expert opinion, we analyzed effectiveness and cost-effectiveness of the use of FET PET in addition to MRI compared with MRI alone for the diagnosis of recurrent brain metastases. Methods A decision-tree model was designed to compare the 2 diagnostic strategies from the perspective of the German Statutory Health Insurance (SHI) system. Effectiveness was defined as correct diagnosis of recurrent brain metastasis and was compared between FET PET with MRI and MRI alone. Costs were calculated for a baseline scenario and for a more expensive scenario. Robustness of the results was tested using sensitivity analyses. Results Compared with MRI alone, FET PET in combination with MRI increases the rate of correct diagnoses by 42% (number needed to diagnose of 3) with an incremental cost-effectiveness ratio of €2821 (baseline scenario) and €4014 (more expensive scenario) per correct diagnosis. The sensitivity analyses confirmed the robustness of the results. Conclusions The model suggests that the additional use of FET PET with conventional MRI for the diagnosis of recurrent brain metastases may be cost-effective. Integration of FET PET has the potential to avoid overtreatment with corresponding costs as well as unnecessary side effects.
Collapse
Affiliation(s)
- Alexander Heinzel
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| | - Dirk Müller
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| | - Sareh Said Yekta-Michael
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| | - Garry Ceccon
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| | - Karl-Josef Langen
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| | - Felix M Mottaghy
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| | - Martin Wiesmann
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| | - Martin Kocher
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| | - Elke Hattingen
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| | - Norbert Galldiks
- Department of Nuclear Medicine, University of Aachen, Aachen, Germany; Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; Department of Conservative Dentistry, Periodontology and Preventive Dentistry, University of Aachen, Aachen, Germany; Department of Neurology, University of Cologne, Cologne, Germany; Institute for Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neuroradiology University of Aachen, Aachen, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany; Department of Radiology, University of Bonn, Bonn, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Germany
| |
Collapse
|
12
|
Burudpakdee C, Wong W, Seetasith A, Corvino F, Yeh W, Gubens M. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. Lung Cancer 2018; 119:103-111. [DOI: 10.1016/j.lungcan.2018.03.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 02/05/2018] [Accepted: 03/08/2018] [Indexed: 10/17/2022]
|
13
|
Lee DH, Isobe H, Wirtz H, Aleixo SB, Parente P, de Marinis F, Huang M, Arunachalam A, Kothari S, Cao X, Donnini N, Woodgate AM, de Castro J. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study. BMC Health Serv Res 2018; 18:147. [PMID: 29490654 PMCID: PMC5831211 DOI: 10.1186/s12913-018-2946-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Accepted: 02/19/2018] [Indexed: 01/10/2023] Open
Abstract
Background Data are scarce regarding real-world health care resource use (HCRU) for non-small cell lung cancer (NSCLC). An understanding of current clinical practices and HCRU is needed to provide a benchmark for rapidly evolving NSCLC management recommendations and therapeutic options. The objective of this study was to describe real-world HCRU for patients with advanced NSCLC. Methods This multinational, retrospective chart review study was conducted at academic and community oncology sites in Italy, Spain, Germany, Australia, Japan, South Korea, Taiwan, and Brazil. Deidentified data were drawn from medical records of 1440 adults (≥18 years old) who initiated systemic therapy (2011 to mid-2013) for a new, confirmed diagnosis of advanced or metastatic (stage IIIB or IV) NSCLC. We summarized HCRU associated with first and subsequent lines of systemic therapy for advanced/metastatic NSCLC. Results The proportion of patients who were hospitalized at least once varied by country from 24% in Italy to 81% in Japan during first-line therapy and from 22% in Italy to 84% in Japan during second-line therapy; overall hospitalization frequency was 2.5–11.1 per 100 patient-weeks, depending on country. Emergency visit frequency also varied among countries (overall from 0.3–5.9 per 100 patient-weeks), increasing consistently from first- through third-line therapy in each country. The outpatient setting was the most common setting of resource use. Most patients in the study had multiple outpatient visits in association with each line of therapy (overall from 21.1 to 59.0 outpatient visits per 100 patient-weeks, depending on country). The use of health care resources showed no regular pattern associated with results of tests for activating mutations of the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene rearrangements. Conclusions HCRU varied across countries. These findings suggest differing approaches to the clinical management of advanced NSCLC among the eight countries. Comparative findings and an understanding of country-specific clinical practices can help to identify areas of need and guide future resource allocation for patients with advanced NSCLC. Further studies evaluating the costs associated with resource use are warranted. Electronic supplementary material The online version of this article (10.1186/s12913-018-2946-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Dae Ho Lee
- Asan Medical Center, Seoul, Republic of Korea
| | | | | | | | - Phillip Parente
- Cancer Services, Box Hill Hospital, and Monash University, Victoria, Australia
| | - Filippo de Marinis
- Thoracic Oncology Division, European Institute of Oncology (IEO), Milan, Italy
| | - Min Huang
- Center for Observational and Real World Evidence (CORE), Merck & Co., Inc., North Wales, PA, USA
| | - Ashwini Arunachalam
- Center for Observational and Real World Evidence (CORE), Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.
| | - Smita Kothari
- Center for Observational and Real World Evidence (CORE), Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| | - Xiting Cao
- Center for Observational and Real World Evidence (CORE), Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| | | | | | - Javier de Castro
- Medical Oncology Service, Hospital Universitario La Paz (IDIPAZ), Madrid, Spain
| |
Collapse
|
14
|
Fernandes AW, Wu B, Turner RM. Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden. J Med Econ 2017; 20:1136-1147. [PMID: 28758857 DOI: 10.1080/13696998.2017.1361960] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
OBJECTIVE This study describes the symptom and economic burden associated with brain metastases (BM) in patients with non-small cell lung cancer (NSCLC) receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs). METHODS This retrospective study included adults with ≥2 medical claims, within 90 days, for lung cancer and ≥1 administration of EGFR-TKIs. Based on ICD-9 codes, patients were stratified into cohorts by type of metastases (BM, other metastases [OM], or no metastases [NM]), and by when the metastasis diagnosis occurred (synchronous or asynchronous). RESULTS The population (synchronous BM [SBM] = 24, synchronous OM [SOM] = 23, asynchronous BM [ASBM] = 15, asynchronous OM [ASOM] = 49, NM = 85) was mostly female (57%), average age 69 years (SD = 11). SBM patients experienced more fatigue and nausea/vomiting compared with SOM and NM patients and more headaches and loss of appetite than NM patients. ASBM was associated with more fatigue, nausea/vomiting, headaches, pain/numbness, altered mental status, and seizures than NM, and more headaches and pain/numbness than ASOM. SBM patients experienced a greater increase in per-member-per-month all-cause total healthcare costs after diagnosis ($20,301) vs SOM ($9,131, p = .001) and NM ($2,493, p = .001). ASBM's cost increase between baseline and follow-up ($7,867) did not differ from ASOM's ($4,947, p = .195); both were larger than NM ($2,493, p = .001 and p = .009, respectively). LIMITATIONS EGFR mutation status was inferred based on EGFR-TKI treatment, not by molecular testing. Patients were from US commercial insurance plans; results may not be generalizable to other populations. CONCLUSIONS Among patients with EGFR-TKI-treated NSCLC, patients with BM experienced more symptoms and, when diagnosed synchronously, had significant increases in total medical costs vs patients with OM and NM. Therapeutic options with central nervous system activity may offer advantages in symptomatology and costs in EGFR-mutated patients with BM.
Collapse
Affiliation(s)
| | - Bingcao Wu
- b Janssen Pharmaceuticals, Inc. , Titusville , NJ , USA
| | | |
Collapse
|
15
|
|
16
|
Guérin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Macalalad AR. The economic burden of brain metastasis among lung cancer patients in the United States. J Med Econ 2016; 19:526-36. [PMID: 26735844 DOI: 10.3111/13696998.2016.1138962] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Brain metastases among lung cancer patients can impair cognitive and functional ability, complicate care, and reduce survival. This study focuses on the economic burden of brain metastasis in lung cancer-direct healthcare costs to payers and indirect costs to patients, payers, and employers-in the US. METHODS Retrospective study using claims data from over 60 self-insured Fortune 500 companies across all US census regions (January 1999-March 2013). Adult, non-elderly lung cancer patients with brain metastasis were evaluated over two study periods: (1) pre-diagnosis (≤30 days prior to first observed lung cancer diagnosis to ≤30 days prior to first-observed brain metastasis diagnosis) and (2) post-diagnosis (≤30 days prior to first observed brain metastasis diagnosis to end of continuous eligibility or observation). OUTCOME MEASURES Healthcare costs to payers and resource utilization, salary loss to patients, disability payouts for payers, and productivity loss to employers. RESULTS A total of 132 patients were followed for a median of 8.4 and 6.6 months in the pre- and post-diagnosis periods, respectively. At diagnosis of brain metastasis, 21.2% of patients were on leave of absence and 6.1% on long-term disability leave. Substantial differences were observed in the pre- vs post-diagnosis periods. Specifically, patients incurred much greater healthcare utilization in the post-diagnosis period, resulting in $25,579 higher medical costs per-patient-per-6-months (PPP6M). During this period, patients missed significantly more work days, generating an incremental burden of $2853 PPP6M in salary loss for patients, $2557 PPP6M in disability payments for payers, and $4570 PPP6M in productivity loss for employers. LIMITATIONS Type of primary lung cancer and extent of brain metastasis could not be assessed in the data. The analysis was also limited to patients with comprehensive disability coverage. CONCLUSIONS Development of brain metastasis among lung cancer patients is associated with a substantial economic burden to payers, patients, and employers.
Collapse
Affiliation(s)
- A Guérin
- a a Analysis Group, Inc. , Montreal , QC , Canada
| | - M Sasane
- b b Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA
| | - K Dea
- a a Analysis Group, Inc. , Montreal , QC , Canada
| | - J Zhang
- b b Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA
| | - K Culver
- b b Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA
| | - R Nitulescu
- a a Analysis Group, Inc. , Montreal , QC , Canada
| | - E Q Wu
- c c Analysis Group, Inc. , Boston , MA , USA
| | | |
Collapse
|
17
|
Cormie P, Nowak AK, Chambers SK, Galvão DA, Newton RU. The potential role of exercise in neuro-oncology. Front Oncol 2015; 5:85. [PMID: 25905043 PMCID: PMC4389372 DOI: 10.3389/fonc.2015.00085] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2014] [Accepted: 03/23/2015] [Indexed: 12/24/2022] Open
Abstract
Patients with brain and other central nervous system cancers experience debilitating physical, cognitive, and emotional effects, which significantly compromise quality of life. Few efficacious pharmacological strategies or supportive care interventions exist to ameliorate these sequelae and patients report high levels of unmet needs in these areas. There is strong theoretical rationale to suggest exercise may be an effective intervention to aid in the management of neuro-oncological disorders. Clinical research has established the efficacy of appropriate exercise in counteracting physical impairments such as fatigue and functional decline, cognitive impairment, as well as psychological effects including depression and anxiety. While there is promise for exercise to enhance physical and psychosocial wellbeing of patients diagnosed with neurologic malignancies, these patients have unique needs and research is urgently required to explore optimal exercise prescription specific to these patients to maximize safety and efficacy. This perspective article is a discussion of potential rehabilitative effects of targeted exercise programs for patients with brain and other central nervous system cancers and highlights future research directions.
Collapse
Affiliation(s)
- Prue Cormie
- Edith Cowan University Health and Wellness Institute, Edith Cowan University , Joondalup, WA , Australia
| | - Anna K Nowak
- School of Medicine and Pharmacology, University of Western Australia , Nedlands, WA , Australia ; Department of Medical Oncology, Sir Charles Gairdner Hospital , Nedlands, WA , Australia
| | - Suzanne K Chambers
- Edith Cowan University Health and Wellness Institute, Edith Cowan University , Joondalup, WA , Australia ; Griffith Health Institute, Griffith University , Southport, QLD , Australia ; Cancer Council Queensland , Brisbane, QLD , Australia ; Prostate Cancer Foundation of Australia , Sydney, NSW , Australia
| | - Daniel A Galvão
- Edith Cowan University Health and Wellness Institute, Edith Cowan University , Joondalup, WA , Australia
| | - Robert U Newton
- Edith Cowan University Health and Wellness Institute, Edith Cowan University , Joondalup, WA , Australia ; The University of Hong Kong , Hong Kong , China
| |
Collapse
|
18
|
Guérin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ 2015; 18:312-22. [PMID: 25565443 DOI: 10.3111/13696998.2014.1003644] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Brain metastases (BM) are highly prevalent among anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) patients; yet little is known about their real-world treatment patterns and clinical and economic burdens. This study aimed to describe these patients' treatment patterns, symptoms, and costs. RESEARCH DESIGN AND METHODS Retrospective study pooling data from three large administrative databases in the US (08/2011-06/2013). ALK+ NSCLC patients with BM and continuous enrollment for ≥ 60 days before and ≥ 30 days after the first observed BM diagnosis were identified by pharmacy records for crizotinib among patients with lung cancer and BM diagnostic codes. MAIN OUTCOME MEASURES Treatment patterns, symptoms, healthcare resource utilization, and costs, before and after BM diagnosis. RESULTS Of the 213 crizotinib patients with BM diagnoses meeting the selection criteria, 23.0% had BM prior to NSCLC diagnosis; 47.4% had BM prior to crizotinib initiation; 19.2% during crizotinib treatment; and 10.3% post-crizotinib treatment. For those diagnosed with BM after NSCLC diagnosis, the median time between the NSCLC and BM diagnoses was 88 days. Following the first observed BM diagnosis, 88.7% used chemotherapy, 63.4% had radiotherapy, and 31.9% had stereotactic radiosurgery. The prevalence of BM-related symptoms substantially increased post-BM-diagnosis: fatigue (from 15% to 39%), headaches (from 5% to 24%), and depression (from 5% to 15%). Monthly costs per patient averaged $5983 before the BM diagnosis and $22,645 after diagnosis. Patients' resource utilization increased significantly post-BM-diagnosis, with a 3-fold increase in OP visits and a 6-fold increase in IP stays. Post-BM-diagnosis costs were driven by pharmacy (42.0%), inpatient (29.6%), and outpatient costs (26.0%). LIMITATIONS The study sample was limited to crizotinib-treated patients. CONCLUSIONS Post-BM-diagnosis, patients experience high symptom burden. Post-BM-diagnosis, treatment is highly variable and costly: average monthly costs per patient almost quadrupled post-BM-diagnosis.
Collapse
|
19
|
Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population. Melanoma Res 2014; 24:602-10. [DOI: 10.1097/cmr.0000000000000097] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|